Patient Preferences for Treatment Features in Neuromyelitis Optica Spectrum Disorder (NMOSD): Results From a Discrete Choice Experiment (DCE) (P7-8.013)
To quantify preferences and predict treatment choices between ravulizumab and other approved treatments (eculizumab, inebilizumab, satralizumab) among US adults with anti-aquaporin-4 antibody-positive (AQP4-Ab+) NMOSD.
Authors
- Christine Poulos (ORCID: https://orcid.org/0000-0001-7810-3411)
- Jeffrey Yu (ORCID: https://orcid.org/0000-0003-3067-6813)
- Kelley Myers (ORCID: https://orcid.org/0000-0002-0936-5677)
- Justin Abbatemarco (ORCID: https://orcid.org/0000-0003-1668-4753)
- Devon Conway (ORCID: https://orcid.org/0000-0001-5359-6686)
- Martin Kleman
Institutions
- Cleveland Clinic (US)
- AstraZeneca (Brazil) (BR)
- RTI Health Solutions (US)
- Alexion Pharma (Switzerland) (CH)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208724
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00